Pegcyte 6mg Injection

About

Pegfilgrastim is a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF), a cytokine that regulates the production and release of neutrophils from the bone marrow. Its primary mechanism involves binding to specific receptors on hematopoietic stem cells, stimulating their proliferation, differentiation, and activation. This leads to a significant increase in neutrophil counts, which are crucial for fighting infections. The pegylation process extends the half-life of filgrastim, allowing for a single dose per chemotherapy cycle, which simplifies administration and improves patient compliance. This sustained action effectively reduces the incidence and duration of severe neutropenia, a common and serious side effect of myelosuppressive chemotherapy. By mitigating the risk of febrile neutropenia, a life-threatening complication, pegfilgrastim helps maintain chemotherapy schedules, reduces the need for dose reductions or delays, and ultimately improves patient outcomes and quality of life during cancer treatment. It plays a vital role in supportive care for oncology patients.

Uses

• Prevention of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy.
• Reduction in the incidence of infection associated with severe neutropenia.
• Supportive care in certain bone marrow transplant settings.
• Mobilization of peripheral blood progenitor cells for autologous transplantation.

Directions For Use

Administer subcutaneously as a single dose per chemotherapy cycle, typically 24 hours after cytotoxic chemotherapy.

Benefits

• Reduces the risk of severe neutropenia.
• Decreases the incidence of febrile neutropenia.
• Allows for timely administration of chemotherapy cycles.
• Minimizes the need for hospitalization due to infection.
• Improves patient quality of life during chemotherapy.
• Convenient single-dose administration per cycle.

Side Effects

• Bone pain
• Myalgia
• Headache
• Nausea
• Fatigue
• Injection site reactions
• Splenic rupture (rare)
• Acute respiratory distress syndrome (rare)
• Allergic reactions
• Glomerulonephritis (rare)
• Leukocytosis
• Thrombocytopenia

Safety Measures

• Alcohol - No specific interaction with alcohol is known; however, alcohol should be consumed in moderation, especially if experiencing fatigue or other systemic side effects.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus. Consult a doctor.
• Breastfeeding - It is unknown if pegfilgrastim is excreted in human milk. Exercise caution; consult a healthcare professional.
• Liver - No specific dose adjustment is typically required for patients with hepatic impairment.
• Kidney - No specific dose adjustment is typically required for patients with renal impairment.
• Lung - Monitor for pulmonary adverse reactions, including acute respiratory distress syndrome (ARDS), especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.